U.S. market Closed. Opens in 16 hours 56 minutes

LFCR | Lifecore Biomedical, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 5.03 - 5.22
52 Week Range 3.68 - 8.90
Beta 0.93
Implied Volatility 343.46%
IV Rank 43.67%
Day's Volume 95,637
Average Volume 304,130
Shares Outstanding 30,898,300
Market Cap 157,272,347
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 1996-02-15
Valuation
Profitability
Growth
Health
P/E Ratio 20.36
Forward P/E Ratio N/A
EPS 0.25
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 524
Country USA
Website LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
*Chart delayed
Analyzing fundamentals for LFCR we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is very poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see LFCR Fundamentals page.

Watching at LFCR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on LFCR Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙